Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia

Fabio P.S. Santos, Hagop Kantarjian, Jorge Cortes, Alfonso Quintas-Cardama

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Fingerprint

Dive into the research topics of 'Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds